Symptoms of liver disease include swelling of the abdomen and legs, bruising easily, changes in the color of stool and urine, and jaundice, or yellowing of the skin and eyes. Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and others therapies are used for the treatment of liver diseases.
The global liver diseases therapeutics market is estimated to account for US$ 12,851.3 Mn in terms of value in 2020 and is expected to reach US$ 24,921.3 Mn by the end of 2027.
Global Liver Diseases Therapeutics Market: Drivers
Increasing approval and launch of novel therapies for the treatment of liver diseases is expected to propel growth of the global liver diseases therapeutics market over the forecast period. For instance, in March 2020, the U.S. Food and Drug Administration (FDA) approved a combination of the checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for people with advanced hepatocellular carcinoma, a liver cancer.
Global Liver Diseases Therapeutics Market: Opportunities
R&D of novel therapies is expected to offer lucrative growth opportunities for players in the global liver diseases therapeutics market. For instance, in April 2020, researchers from Osaka City University Graduate School of Medicine, Japan, in the Journal of Hepatology, reported novel highlights in the pathophysiology of human nonalcoholic steatohepatitis with fibrosis and suggested a new approach for the treatment of the condition using cytoglobin inducer.
Global Liver Diseases Therapeutics Market: Restraints
Absence of effective therapeutics for the treatment of hepatocellular carcinoma is expected to hinder growth of the market. Treatment of liver cancer is largely limited to chemotherapy or surgical removal. However, liver naturally resists to damage by chemicals, which makes chemotherapy a less effective approach.
The global liver diseases therapeutics market was valued at US$ 11,854.7 Mn in 2019 and is forecast to reach a value of US$ 24,921.3 Mn by 2027 at a CAGR of 9.7% between 2020 and 2027. Increasing prevalence of diseases such as hepatitis and liver cancer is expected to support growth of the market over the forecast period.
Antiviral drugs segment held dominant position in the global liver diseases therapeutics market in 2019, accounting for 32.7% share in terms of value, followed by vaccines and chemotherapy drugs, respectively. Antiviral drugs are used in the treatment of hepatitis, and new drug launches are expected to support growth of this segment.
Hospital Pharmacies segment held dominant position in the global liver diseases therapeutics market in 2019, accounting for 41.3% share in terms of value, followed by retail pharmacies and online pharmacies, respectively.
The U.S. is witnessing increase in cases of hepatitis C virus (HCV) infection. For instance, in April 2020, the Centers for Disease Control and Prevention stated the rate of new HCV infections increased by about 300% among people ages 20 to 29 and by about 400% among those ages 30 to 39.
The market is witnessing R&D in liver fibrosis. For instance, in March 2020, Theratechnologies Inc., a commercial-stage biopharmaceutical company, announced a data presentation that demonstrated relation of visceral fat in the prediction of liver fibrosis and liver fibrosis progression.
Global Liver Diseases Therapeutics Market: Competitive Landscape
Major players operating in the global liver diseases therapeutics market include, Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Global Liver Diseases Therapeutics Market: Key Developments
April 2020: Provectus Biopharmaceuticals Inc.’s data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent and in combination with immune checkpoint blockade for the treatment of primary or metastatic tumors of the liver was uploaded to the SIR 2020 ePoster Gallery of the canceled Society of Interventional Radiology 2020 Annual Scientific Meeting.
March 2020: MAX BioPharma, Inc. announced, through a published article, the efficacy of its anti-tumorigenic oxysterol lead compound, Oxy210, in the treatment of liver fibrosis